Genor Biopharma Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Genor Biopharma Holdings CEO'su Feng Guo, Apr2020 tarihinde atandı, in görev süresi 4.58 yıldır. in toplam yıllık tazminatı CN¥ 24.29M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.5% maaş ve 81.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.35% ine doğrudan sahiptir ve bu hisseler HK$ 13.05M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 2.9 yıldır.

Anahtar bilgiler

Feng Guo

İcra Kurulu Başkanı

CN¥24.3m

Toplam tazminat

CEO maaş yüzdesi	18.5%
CEO görev süresi	4.6yrs
CEO sahipliği	1.3%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10

CEO Tazminat Analizi

Feng Guo'un ücretlendirmesi Genor Biopharma Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥526m
Mar 31 2024	n/a	n/a	-CN¥600m
Dec 31 2023	CN¥24m	CN¥5m	-CN¥674m
Sep 30 2023	n/a	n/a	-CN¥637m
Jun 30 2023	n/a	n/a	-CN¥599m
Mar 31 2023	n/a	n/a	-CN¥665m
Dec 31 2022	CN¥32m	CN¥5m	-CN¥730m
Sep 30 2022	n/a	n/a	-CN¥800m
Jun 30 2022	n/a	n/a	-CN¥870m
Mar 31 2022	n/a	n/a	-CN¥868m
Dec 31 2021	CN¥41m	CN¥5m	-CN¥865m

Tazminat ve Piyasa: Feng 'nin toplam tazminatı ($USD 3.41M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 235.07K ).

Tazminat ve Kazançlar: Feng 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Feng Guo (54 yo)

4.6yrs

Görev süresi

CN¥24,285,000

Tazminat

Dr. Feng Guo Ph D., served as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021 until September 12, 2024.He served as Chairman at Genor Biopharma Holdings Limited since November 02,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Feng Guo	Chief Executive Officer	4.6yrs	CN¥24.29m	1.35% HK$ 13.1m
Chengyi Weng	CFO, Company Secretary & Executive Director	no data	Veri yok	0.067% HK$ 648.6k
Qibin Liang	Chief Technology Officer	3.1yrs	Veri yok	Veri yok
Shuhua Han	Chief Scientist	3.8yrs	Veri yok	Veri yok
Xiaojing Zhu	Vice President of Compliance & Administration	no data	Veri yok	Veri yok
Tong Li	Chief Medical Officer	4.3yrs	Veri yok	Veri yok
Tak Wai Ip	Company Secretary	2.4yrs	Veri yok	Veri yok
Jun Lin	Vice President of Quality Analysis	4.8yrs	Veri yok	Veri yok
Qingtang Duan	General Manager of Yuxi Genor	5.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: 6998 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chengyi Weng	CFO, Company Secretary & Executive Director	less than a year	Veri yok	0.067% HK$ 648.6k
David J. Kerr	Member of Scientific Advisory Board	2.9yrs	Veri yok	Veri yok
Leonard B. Saltz	Member of Scientific Advisory Board	2.9yrs	Veri yok	Veri yok
Wen Chen	Independent Non-Executive Director	4.4yrs	CN¥420.00k	Veri yok
Alex A. Adjei	Member of Scientific Advisory Board	2.9yrs	Veri yok	Veri yok
Edwin Fung	Independent Non-Executive Director	4.4yrs	CN¥420.00k	Veri yok
Dong Lyu	Non Executive Director	3yrs	Veri yok	Veri yok
Zhijian Chen	Chairman of Scientific Advisory Board	3.5yrs	Veri yok	Veri yok
Yangxin Fu	Member of Scientific Advisory Board	2.9yrs	Veri yok	Veri yok
John F. Seymour	Member of Scientific Advisory Board	2.9yrs	Veri yok	Veri yok
John R. Zalcberg	Member of Scientific Advisory Board	2.9yrs	Veri yok	Veri yok
Yi Liu	Non-Executive Director	2.3yrs	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6998 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Genor Biopharma Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genor Biopharma Holdings Limited Appoints Cui Bai as Independent Non-Executive Director and Member of the Audit Committee of the Board

Genor Biopharma Holdings Limited Announces Resignation of Zhou Honghao as Independent Non-Executive Director and Member of the Audit Committee

Genor Biopharma Holdings Limited Appoints Weng Chengyi as Chief Financial Officer

Genor Biopharma Holdings Limited Announces Directorate Changes

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Genor Biopharma Holdings Limited, Annual General Meeting, Jun 27, 2024

Recent updates

Edding Group Company Limited agreed to acquire Genor Biopharma Holdings Limited (SEHK:6998).

Genor Biopharma Holdings Limited Appoints Cui Bai as Independent Non-Executive Director and Member of the Audit Committee of the Board

Genor Biopharma Holdings Limited Announces Resignation of Zhou Honghao as Independent Non-Executive Director and Member of the Audit Committee

Genor Biopharma Holdings Limited Appoints Weng Chengyi as Chief Financial Officer

Genor Biopharma Holdings Limited Announces Directorate Changes

New minor risk - Shareholder dilution

Genor Biopharma Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

Genor Biopharma Holdings Limited, Annual General Meeting, Jun 27, 2024

Genor Biopharma Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Genor Biopharma Holdings Limited Announces China National Medical Products Administration Accepts New Drug Application for GB491 (Lerociclib)

New minor risk - Share price stability

Genor Biopharma Holdings Limited Announces Board Changes

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

First half 2023 earnings released: CN¥0.54 loss per share (vs CN¥0.81 loss in 1H 2022)

Genor Biopharma Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Market cap size

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Consensus forecasts updated

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

JHBP (CY) Holdings Limited Submits a Clinical Trial Application to the Bellberry Human Research Ethics Committee in Australia

JHBP (CY) Holdings Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

JHBP (Cy) Holdings Limited Receives Drug Approvals from the National Medical Products Administration

JHBP (CY) Holdings Limited Appoints Han Shuhua as New Chief Scientist

New 90-day high: HK$23.00

JHBP (CY) Holdings Limited has completed an IPO in the amount of HKD 2.877144 billion.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş